SPY363.22+5.76 1.61%
DIA300.43+4.54 1.53%
IXIC12,036.79+156.15 1.31%

BeyondSpring Phase 3 PROTECTIVE-2 Study Met it Primary Endpoint

Study met primary endpoint showing statistically significant improvement in rate of prevention of Grade 4 neutropenia in Cycle 1, p=0.0015   Study met statistically

· 11/16/2020 07:09
  • Study met primary endpoint showing statistically significant improvement in rate of prevention of Grade 4 neutropenia in Cycle 1, p=0.0015


     
  • Study met statistically significant improvement in key secondary endpoints, including DSN Cycle 1 D1-8, DSN Cycle 1and Mean ANC Nadir Cycle 1


     
  • Plinabulin in combination with pegfilgrastim, a Breakthrough Designation therapy, is believed to be the first product candidate to show improvement over standard of care (G-CSF monotherapy) for chemotherapy-induced neutropenia (CIN), a complication which affects as many as 440,000 chemotherapy patients in the U.S. annually
     
  • Conference call and webcast to discuss results will bheld today at 8:30 a.m. ET